Xiaohua Su

Title: Innovations in Antiviral Therapies: The Contributions of Xiaohua Su

Introduction

Xiaohua Su is an innovative inventor based in Houston, TX, who has made significant contributions to the field of antiviral therapies. With a focus on developing effective treatments for Covid-19 and other viral infections, her work has the potential to impact public health significantly.

Latest Patents

Xiaohua Su holds a patent for "Nuclease-dendrimer formulations for Covid-19 and broad-spectrum antiviral therapy and prophylaxis." This patent describes compositions of nucleases in formulations with dendrimers that are used in pharmaceutically effective dosages as therapeutics for Covid-19 and a broad spectrum of viruses. The invention highlights the unexpected positive dendrimer effect when cationized nucleases are mixed and/or complexed with a dendrimer, which enhances the anti-viral RNase properties. The compositions demonstrate a synergistic amplification of anti-viral effectiveness, making them valuable in the fight against Covid-19 and various other viruses.

Career Highlights

Xiaohua Su's career is marked by her dedication to research and innovation in the pharmaceutical field. Her work at Fulu Labs Corporation has allowed her to explore groundbreaking solutions to pressing health challenges.

Collaborations

Xiaohua collaborates with Leonid I Rudin, contributing to the advancement of antiviral therapies through their combined expertise and research efforts.

Conclusion

Xiaohua Su's innovative work in developing antiviral therapies showcases her commitment to improving health outcomes. Her contributions are vital in the ongoing battle against viral infections, particularly in the context of the Covid-19 pandemic.